Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Haemonetics Corporation, Omnicell or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Haemonetics Corporation, Omnicell and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Haemonetics Corporation, Omnicell and Inc.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Latest Health Care Equipment & Supplies and Haemonetics Corporation, Omnicell, Inc. Stock News

As of December 16, 2025, Haemonetics Corporation had a $3.8 billion market capitalization, compared to the Health Care Equipment & Supplies median of $333.0 million. Haemonetics Corporation’s stock is up 2.4% in 2025, down 8.2% in the previous five trading days and down 1.45% in the past year.

Currently, Haemonetics Corporation’s price-earnings ratio is 23.6. Haemonetics Corporation’s trailing 12-month revenue is $1.3 billion with a 12.7% net profit margin. Year-over-year quarterly sales growth most recently was -5.3%. Analysts expect adjusted earnings to reach $4.914 per share for the current fiscal year. Haemonetics Corporation does not currently pay a dividend.

As of December 16, 2025, Omnicell, Inc. had a $2.0 billion market cap, putting it in the 56th percentile of all stocks. Omnicell, Inc.’s stock is up 2.9% in 2025, up 4.1% in the previous five trading days and down 2.65% in the past year.

Currently, Omnicell, Inc.’s price-earnings ratio is 105.3. Omnicell, Inc.’s trailing 12-month revenue is $1.2 billion with a 1.7% net profit margin. Year-over-year quarterly sales growth most recently was 10.0%. Analysts expect adjusted earnings to reach $1.710 per share for the current fiscal year. Omnicell, Inc. does not currently pay a dividend.

How We Compare Haemonetics Corporation, Omnicell and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Haemonetics Corporation, Omnicell and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Haemonetics Corporation, Omnicell and Inc. Stock Value Grades

Company	Ticker	Value
Haemonetics Corporation	HAE	C
Omnicell, Inc.	OMCL	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Haemonetics Corporation has a Value Score of 43, which is Average. Omnicell, Inc. has a Value Score of 34, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Haemonetics Corporation, Omnicell or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Haemonetics Corporation, Omnicell or Inc. is the better investment when it comes to value.

Haemonetics Corporation, Omnicell and Inc.’s Momentum Grades

Company	Ticker	Momentum
Haemonetics Corporation	HAE	A
Omnicell, Inc.	OMCL	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Haemonetics Corporation has a Momentum Score of 85, which is Very Strong. Omnicell, Inc. has a Momentum Score of 76, which is Strong.

The Momentum Grade Winner: Haemonetics Corporation

As you can clearly see from the Momentum Grade breakdown above, Haemonetics Corporation is considered to have stronger momentum compared to Omnicell, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Haemonetics Corporation could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Haemonetics Corporation, Omnicell and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Haemonetics Corporation	HAE	C
Omnicell, Inc.	OMCL	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Haemonetics Corporation has a Earnings Estimate Score of 58, which is Neutral. Omnicell, Inc. has a Earnings Estimate Score of 69, which is Positive.

The Earnings Estimate Revisions Grade Winner: Omnicell, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Omnicell, Inc. has a better Earnings Estimate Revisions Grade than Haemonetics Corporation. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Omnicell, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Haemonetics Corporation, Omnicell and Inc. Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Haemonetics Corporation, Omnicell and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Haemonetics Corporation, Omnicell or Inc. Stock?

Overall, Haemonetics Corporation stock has a Value Score of 43, Momentum Score of 85 and Estimate Revisions Score of 58.

Omnicell, Inc. stock has a Value Score of 34, Momentum Score of 76 and Estimate Revisions Score of 69.

Comparing Haemonetics Corporation, Omnicell and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.